REG - OptiBiotix Health - SlimBiome® contract manufacturing agreement

OptiBiotix HealthAnnouncement

06/04/2020 07:06

RNS Number : 7909I
  
OptiBiotix Health PLC
  
06 April 2020
  
 

OptiBiotix Health plc
("OptiBiotix" or the "Company")
 
SlimBiome® contract manufacturing agreement with Laboratoire PYC Inc.
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces it has entered into a contract manufacturing agreement with Laboratoire PYC  Inc. ("Laboratoire PYC") in France.
 
Laboratoire PYC (https://www.laboratoire-pyc.com/en/company/) develops, manufactures and packages private label food supplements, nutricosmetics and high protein & sport nutrition products. Laboratoire PYC has more than 30 years of experience and belongs to the Solina Group (https://solina-group.com), a group with a turnover of approximately €450 million. The terms of the agreement grant Laboratoire PYC the exclusive rights to manufacture a new type of meal replacement shakes designed specifically to support the international expansion of  OptiBiotix's own label GoFigure® consumer weight management brand. 
 
This is another strategic step by OptiBiotix to de-risk its supply chain. The deal builds on the recent partnership with Fipros A/S in Denmark to produce SlimBiome under licence within the European Union (RNS: 2 April 2020) and creates a source of supply of GoFigure® products located within the European Union to support the international growth of  the B2C brand in Poland (RNS: 6 December 2019), in Malaysia and Singapore (RNS: 6 December 2019) and Eastern Europe (RNS: 24 March 2020).
 
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to work with Laboratoire PYC to manufacture a new range of meal replacement shakes formulated with SlimBiome®, and sold under the GoFigure® brand. The agreement helps us lower the cost of trade in case of a hard Brexit, supports our existing and future European distributors, and builds contingency into the supply chain: a key requirement from large retail partners who do not want to be single-sourced. In addition, Laboratoire PYC has a large portfolio of product formulations which can be formulated with SlimBiome® enabling us to increase the number of applications, extend our product range, and shorten the development of new GoFigure®, SnackSmart® and SnackWell® products without incurring significant development costs." 
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
For further information, please contact:
 



OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below














Cairn Financial Advisers LLP (NOMAD)


Tel: 020 7213 0880




Liam Murray / Jo Turner / Ludovico Lazzaretti


















finnCap (Broker)


Tel: 020 7220 0500




Geoff Nash / Kate Bannatyne (Corporate Finance)








Camille Gochez (Corporate Broking)


 








 




goetzpartners securities Limited


Tel: 0203 859 7725




Ulrich Kinzel 


















Walbrook PR Ltd


Mob: 07876 741 001




Anna Dunphy












 
 
 
 
 
About OptiBiotix - www.optibiotix.com 
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 
 
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
 
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 
 
 
 
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
AGRIJMITMTJMBMM